Physician profile
Dong Shin
NPI 1740387646
$6,159.91
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,668 · 2020: $737 · 2021: $984 · 2022: $1,301 · 2023: $1,053 · 2024: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,469.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,270.66 | 2019-2023 | Farxiga |
| Abbvie INC. | $626.48 | 2019-2023 | Linzess, Viberzi, Creon |
| Bayer Healthcare Pharmaceuticals INC. | $494.11 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $472.76 | 2019-2022 | |
| Glaxosmithkline, LLC. | $371.40 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $246.63 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $221.31 | 2020-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $219.68 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.07 | 2021-2024 | Jardiance |
| Lilly USA, LLC | $218.58 | 2019-2024 | Jardiance, Mounjaro, Trulicity |
| Sumitomo Pharma America, INC. | $200.28 | 2023 | Gemtesa |
| Novo Nordisk INC | $181.39 | 2019-2024 | Ozempic, Rybelsus |
| Nestle Healthcare Nutrition INC. | $178.00 | 2021-2023 | |
| Amarin Pharma, INC. | $135.03 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $134.88 | 2019-2023 | Belsomra, Januvia |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $104.78 | 2022-2024 | Repatha, Otezla |
| Redhill Biopharma INC. | $103.00 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $93.90 | 2021-2022 | |
| Corium, LLC | $89.77 | 2022-2023 | Adlarity |
| Eisai INC. | $89.14 | 2020-2021 | |
| Pfizer INC. | $75.11 | 2019-2023 | |
| Ironwood Pharmaceuticals, INC | $70.71 | 2022-2024 | |
| Scilex Pharmaceuticals INC. | $57.62 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $46.14 | 2024 | Voquezna |
| Vivus LLC | $32.50 | 2023 | Pancreaze |
| Gilead Sciences, INC. | $29.56 | 2023 | |
| Digestive Care, INC. | $24.57 | 2024 | Pertzye |
| Sunovion Pharmaceuticals INC. | $24.56 | 2022 | |
| Novartis Pharmaceuticals Corporation | $24.16 | 2022 | |
| Xeris Pharmaceuticals, INC. | $23.56 | 2022 | |
| Eyevance Pharmaceuticals LLC | $23.33 | 2021 | |
| Astellas Pharma US INC | $19.65 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.29 | 2022 | |
| Ibsa Pharma INC. | $18.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dong Shin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.